Achieving A1C and Glycemic Targets with Insulin What to Do When Oral Agents Fail New Paradigms, Guidelines, and Evolving Strategies JUAN P. FRIAS, M.D.,
The Case for Going Coo-coo for Cacao -data, from the dark side- David L. Katz, MD, MPH, FACPM, FACP Director, Prevention Research Center Yale University.
Nitrattherapie und Nitratresistenz – Implikationen für Diabetes mellitus und KHK Nitrattherapie und Nitratresistenz – Implikationen für Diabetes mellitus.
09-Aug-2008-JAN-2007-BE-1263-SS Adapted from Buse JB et al. In Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders, 2003:1427–1483; Buchanan.
Ir call 2014_ada_final
SGLT2 Endocrine CME Grand Rounds Final
1erafechajanumetvsglimepiridamasmetforminaeficaciacomparativadeterapiascombinadas-121226222922-phpapp02.ppt
Analogue Insulin, The New Tools to Challenges Diabetes 3
What’s New in Diabetes Maeve C. Durkan MBBS, FACP, Mmed.Ed Consultant in Diabetes, Endocrinology & Metabolism.
HYPOGLYCEMIA IN DIABETES Sue Pedersen, MD, FRCPC Specialist in Endocrinology & Metabolism C-ENDO Endocrinology Centre, Calgary Rocky Mountain GIM Conference.
Natalie Alméras, Ph.D . Quebec Heart and Lung Institute
Diabetes tipo 2 es un desorden heterogéneo